Clinical Trial Search

Primary: Percentage of Participants With Sustained Viral Response (SVR) at Week 24 — 87.2; 94.8; 85.2 Percentage of Participants

Primary: Immediate Reactions Occurring Within 60 Minutes of Administration of Any Dose — 0; 0; 0; 0 Participants

Primary: Total Sleep Time as Measured by Fitbit Charge2 or Microsoft Band2. — 437.0; 394.9 minutes — p=<0.001

Primary: Number of Participants Assessed for Donor Site Complications and Muscle Flap Viability — 15 Participants

Primary: Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I) — -12; -7 units on a scale — p=.44

Primary: Mean Change From Baseline in QTc Interval (Corrected by Friderica's Formula, dQTcF) Associated With Plasma Moxidectin Concentrations After a Single Dose — -5.1; -4.5…

Primary: Visual Analog Scale — 2.65; 2.50 units on a scale

Primary: Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies — 83; 86 Participants

Primary: Percentage of Participants Who Experienced Increase and Maintain Hemoglobin Levels (Two Consecutive Values) Greater Than or Equal to the Lower Limit of the Target Range…

Primary: Number of Participants in Which H. Pylori Was Eradicated — 13; 21 participants

Primary: Alcohol Craving — 2.89; 3.08 scores on a scale

Primary: Adverse Events — 15; 16 Participants

Primary: Area Under the Plasma Concentration-Time Curve From Zero Time (Predose) to Time of Last Quantifiable Concentration (AUC(0-t)) — 1010; 1010; 965 ng·hr/mL — p=0.8826

Primary: Number of Participants in Which H. Pylori Was Eradicated — 36; 49 participants — p=<0.001

Primary: Engraftment as Measured by Donor Chimerism — 91 percentage of participants